CIK relay cell immunotherapy is a kind of biological therapy, and medical science has proved that CIK cells are the best method of next-generation relay cell therapy. It has been applied in clinical practice and has good therapeutic effect on malignant tumors such as leukemia, melanoma, malignant lymphoma, renal cell carcinoma, metastatic kidney cancer, lung cancer, liver cancer, breast cancer, colon cancer and stomach cancer.
CIK cells (cytokine-induced killer) are a kind of immune cells in human body, which are non-MHC-restricted in killing tumor cells, i.e. not restricted by cancer tissue type, and can automatically recognize and kill tumor cells in a wide range of sites in human body. CIK cells in normal human peripheral blood only account for 1-5% of lymphocytes, and their decreased number and diminished function are closely related to the occurrence and development of tumors. With our culture technology, however, the number can be increased thousands of times and the ability to kill cancer cells can be enhanced tens of times.
Under in vitro conditions, human peripheral blood mononuclear cells (PBMC) are induced to become CIK cells after co-stimulation with various cytokines (e.g. IFN-γ, IL-1, IL-2, anti-CD3 mAb), with both surface markers of T cells (TCR-α/β, CD3) and NK cells (CD56) on the surface of their main effector cells. Compared with lymphokine-activated killer (LAK) and tumor-infiltrating lymphocytes (TIL), which have been used in the past for secondary immunotherapy, CIK has a stronger cell proliferation capacity and stronger anti-tumor cell effects. The treatment can directly kill tumor cells without damaging the structure and function of the immune system, and regulate and enhance the immune function of the body, restoring the normal growth regulation of cells to the greatest extent possible, providing a new way for thorough tumor treatment.